argenx - ARGX Stock Forecast, Price & News

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ARGX. Morgan Stanley upped their price target on shares of argenx from $375.00 to $401.00 and gave the stock an "overweight" rating in a report on Friday, July 29th. JPMorgan Chase & Co. upped their target price on shares of argenx from €390.00 ($397.96) to €430.00 ($438.78) and gave the stock an "overweight" rating in a research report on Thursday, July 14th. Deutsche Bank Aktiengesellschaft upgraded shares of argenx from a "hold" rating to a "buy" rating in a research report on Friday, May 13th. SVB Leerink upped their target price on shares of argenx from $404.00 to $428.00 and gave the stock an "outperform" rating in a research report on Friday, July 29th. Finally, Robert W. Baird reiterated a "downgrade" rating on shares of argenx in a research report on Friday, July 29th. One equities research analyst has rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $395.00.

argenx Trading Up 1.6 %

Shares of ARGX Stock opened at $382.86 on Tuesday. argenx has a 12-month low of $249.50 and a 12-month high of $388.06. The firm's 50 day moving average is $360.53 and its 200 day moving average is $322.10. The stock has a market capitalization of $21.08 billion, a P/E ratio of -22.09 and a beta of 0.84.